An observational study in Axial Spondyloarthritis, sponsored by Association de Recherche Clinique en Rhumatologie. Completed at 18 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-27.
Sponsored by Association de Recherche Clinique en Rhumatologie · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Axial Spondyloarthritis with a site in France — 9 open to participants now, 11 under way, 3 of them phase 3. Axial Spondyloarthritis · France.
Among the 40 studies in Axial Spondyloarthritis with a site in France, this one is the 8th largest by enrollment of the 10 observational ones that give a count, is one of 2 that started in 2016, is one of 10 observational ones, and was the 10th registered.
187 studies on the registry are indexed under Axial Spondyloarthritis; 57 are open to participants now.
Browse Axial Spondyloarthritis studies →9 of the 40 studies in Axial Spondyloarthritis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Association de Recherche Clinique en Rhumatologie · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–75
Centre Hospitalier Universitaire de Besancon · Sites in France
Ages 18–80
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 39 Axial Spondyloarthritis studies recruiting now, 20 (51%) set no upper age limit and 13 (33%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 13 · Phase 4 2
First in 2009; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 163 is close to the median of 180 across 61 observational studies indexed under Axial Spondyloarthritis.
Median enrollment 188 across the 30 interventional studies, 413 across the 10 observational. Of the 27 that completed or were terminated, 12 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 40 have an industry lead sponsor. The 10 most frequent:
Association de Recherche Clinique en Rhumatologie is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Association de Recherche Clinique en Rhumatologie has 3 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654753Phase 3Assistance Publique - Hôpitaux de ParisThe Efficacy of Fecal Microbiota Transplatation on Axial Spondyloarthritis Patients Resistant to Conventional Treatment | 2027-09 |
| NCT06259890Centre Hospitalier Universitaire de BesanconInfluence of Sodium Intake in spondyLoarthriTes | 2026-11 |
| NCT04286373Assistance Publique - Hôpitaux de ParisEfficacy of Non-invasive Vagus Nerve Stimulation for Axial Spondyloarthritis Resistant to Biotherapies | 2026-12 |
| NCT07141017Association de Recherche Clinique en RhumatologieInitial Standardized Global Review in Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 40 studies in Axial Spondyloarthritis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a not interventional, pragmatic, prospective, randomized (cluster) study to evaluate the potential benefit of a Treat to Target approach in comparison to routine treatment (i.e. usual care) in patients with axial spondyloarthritis.
This study is reflecting the usual care either in accordance to the treating rheumatologist (arm: usual care) or in accordance to the international scientific recommendations (arm: T2T)
The tight control means that as soon as a treatment is initiated in a patient, the time permitting to evaluate its potential efficacy/safety has to be determined. In terms of safety, such time frame can be very short based on the occurrence of adverse events. In terms of efficacy it is usually recommended to evaluate an NSAIDs after 2 to 4 weeks of treatment intake and the TNF blockers after 12 to 16 weeks.
The Treat to Target means that there is an a priori decision of the target to reach while initiating a treatment and more importantly an a priori decision to intensify the treatment in case such target is not achieved.
There will be 2 arms in the study (tight control and treat to target arm and usual care arm).
160 patients (80 patients per arm) will be included during one year by 18 centers (10 in France, 4 in Belgium and 4 in Netherlands). Patients will be followed during 1 year.
Patient with a diagnosis of predominant axial spondyloarthritis according to the axial ASAS criteria AND the opinion of the treating rheumatologist, and an active disease defined as an (ASDAS ≥ 2.1), and non-optimally treated with NSAIDs.
Inclusion Criteria:
Predominant axial disease meaning that:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For this group, the treating rheumatologist will agree to monitor very closely (at least every 4 weeks) and also to treat their patients in accordance with a pre-defined strategy.
Other: Follow-up every 3 months during 1 year (data collection in eCRF) · Other: Follow-up every month to follow the pre-defined strategy
For this arm, the treating rheumatologists will continue to manage the enrolled patients in accordance to their usual care.
Other: Follow-up every 3 months during 1 year (data collection in eCRF)
To compare the changes in ASASHI-NRS over the one year of follow-up in the 2 groups
In the original protocol, the main objective was "to compare the percentage of patients with a significant improvement in the ASAS-HI score after a one year follow-up in the 2 groups". However, after further research on the methodology to better assess the treatment effect on a pragmatic cluster-based strategy trial, we propose to change the primary objective for two reasons in order to: * Calculate a "significant improvement" of the ASAS-HI, we would need to be aware of the minimally clinically important difference, and this threshold has not been yet defined for the regular ASAS-HI nor for the ASAS-HI NRS. * Account for the reduced heterogeneity induced by the fact that patients are clustered, a multilevel analysis (e.g. mixed models with two random effects, the subject and the cluster or center) has been proposed as the most appropriate method. Therefore, we have amended the main objective to: "To compare the changes in ASASHI-NRS over the one year of follow-up in the 2 groups".
Time frame: After a one year follow-up
To compare the percentage of patients reaching an ASDAS major improvement after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the percentage of patients reaching an ASDAS clinically important improvement after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the percentage of patients reaching a BASDAI 50 after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the change in the ASDAS over one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the change in the BASDAI over one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the change in the ASAS-NSAID score over one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the WPAI after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the EQ5D after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the self-report questionnaire on health resource utilization after a one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the number and type of adverse events occuring over one year follow-up in the 2 groups.
Time frame: After a one year follow-up
To compare the treatment effect (...) within the T2T depending on the compliance to the T2T treatment.
Time frame: After a one year follow-up
Plan to share: No
Ran from Nov 2016 to primary completion in Jun 2019, 30 months.
Of 28 observational studies under Axial Spondyloarthritis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's 30 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Association de Recherche Clinique en Rhumatologie